{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T05:13:07Z","timestamp":1771823587256,"version":"3.50.1"},"reference-count":33,"publisher":"Jaypee Brothers Medical Publishing","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.59556\/japi.74.1301","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T04:38:05Z","timestamp":1771821485000},"page":"43-45","source":"Crossref","is-referenced-by-count":0,"title":["Mineralocorticoid Receptor Antagonist and Its Combinations in Heart Failure"],"prefix":"10.59556","volume":"74","author":[{"given":"Kiron","family":"Varghese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajeev","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J K","family":"Rath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kisor K","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramesh","family":"Dargad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Gutghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tejpal","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laxmidas","family":"Ganatra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dev K","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Febin","family":"Francis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amarnath","family":"Sugumaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Senthilnathan","family":"Mohanasundaram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2914","reference":[{"issue":"(18):","key":"key20260223043755_B1","first-page":"e895\u2013","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines.","volume":"145","author":"Heidenreich","year":"2022;","journal-title":"Circulation"},{"issue":"(17):","key":"key20260223043755_B2","doi-asserted-by":"crossref","first-page":"1905\u2013","DOI":"10.1001\/archinte.1994.00420170045004","article-title":"Diuretic treatment for the sodium retention of congestive heart failure.","volume":"154","author":"Cody","year":"1994;","journal-title":"Arch Intern Med"},{"issue":"(13).","key":"key20260223043755_B3","article-title":"Eligibility for the 4 pharmacological pillars in heart failure with reduced ejection fraction at discharge.","volume":"12","author":"D'Amario","year":"2023;","journal-title":"JAHA"},{"issue":"(10):","key":"key20260223043755_B4","doi-asserted-by":"crossref","first-page":"709\u2013","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.","volume":"341","author":"Pitt","year":"1999;","journal-title":"N Engl J Med"},{"issue":"(1):","key":"key20260223043755_B5","doi-asserted-by":"crossref","first-page":"11\u2013","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms.","volume":"364","author":"Zannad","year":"2011;","journal-title":"N Engl J Med"},{"key":"key20260223043755_B6","author":"Kanderi","year":"2023."},{"issue":"(1.2):","key":"key20260223043755_B7","doi-asserted-by":"crossref","first-page":"41\u2013","DOI":"10.2152\/jmi.70.41","article-title":"Benefits of guideline-directed medical therapy to loop diuretics in management of heart failure.","volume":"70","author":"Kusunose","year":"2023;","journal-title":"J Med Invest"},{"issue":"(8):","key":"key20260223043755_B8","doi-asserted-by":"crossref","first-page":"1248\u2013","DOI":"10.2215\/CJN.09630818","article-title":"Clinical pharmacology in diuretic use.","volume":"14","author":"Ellison","year":"2019;","journal-title":"CJASN"},{"issue":"(1):","key":"key20260223043755_B9","doi-asserted-by":"crossref","first-page":"56\u2013","DOI":"10.1161\/CIRCHEARTFAILURE.108.821785","article-title":"Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil?","volume":"2","author":"Felker","year":"2009;","journal-title":"Circ Heart Fail"},{"issue":"(12):","key":"key20260223043755_B10","doi-asserted-by":"crossref","first-page":"1311\u2013","DOI":"10.1161\/01.CIR.100.12.1311","article-title":"Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction.","volume":"100","author":"Cooper","year":"1999;","journal-title":"Circulation"},{"issue":"(7):","key":"key20260223043755_B11","doi-asserted-by":"crossref","first-page":"1423\u2013","DOI":"10.1161\/HYPERTENSIONAHA.122.19159","article-title":"Mineralocorticoid receptor antagonists cause natriuresis in the absence of aldosterone.","volume":"79","author":"Maeoka","year":"2022;","journal-title":"Hypertension"},{"issue":"(11):","key":"key20260223043755_B12","doi-asserted-by":"crossref","first-page":"2345\u2013","DOI":"10.1097\/HJH.0b013e3282e9a72d","article-title":"Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure.","volume":"25","author":"Shah","year":"2007;","journal-title":"J Hypertens"},{"issue":"(5):","key":"key20260223043755_B13","doi-asserted-by":"crossref","first-page":"605\u2013","DOI":"10.1517\/14656566.2014.879117","article-title":"Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents.","volume":"15","author":"Tamargo","year":"2014;","journal-title":"Expert Opin Pharmacother"},{"issue":"(1):","key":"key20260223043755_B14","doi-asserted-by":"crossref","first-page":"17\u2013","DOI":"10.1136\/hrt.57.1.17","article-title":"Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics.","volume":"57","author":"Bayliss","year":"1987;","journal-title":"Heart"},{"issue":"(2):","key":"key20260223043755_B15","doi-asserted-by":"crossref","first-page":"57\u2013","DOI":"10.1007\/s11897-019-0424-1","article-title":"Diuretic resistance in heart failure.","volume":"16","author":"Gupta","year":"2019;","journal-title":"Curr Heart Fail Rep"},{"issue":"(1):","key":"key20260223043755_B16","doi-asserted-by":"crossref","first-page":"5\u2013","DOI":"10.1097\/MJT.0b013e31813e6452","article-title":"Effects of increased dose of diuretics on symptoms, weight, 6-minute walk distance, and echocardiographic measurements of left ventricular systolic and diastolic function in 51 patients with symptomatic heart failure caused by reduced left ventricular ejection fraction treated with beta blockers and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.","volume":"16","author":"Kumar","year":"2009;","journal-title":"Am J Ther"},{"issue":"(1):","key":"key20260223043755_B17","first-page":"A12572.","article-title":"Abstract 12572: safety and efficacy of high dose spironolactone in loop diuretic resistant acute decompensated heart failure.","volume":"138","author":"Velagapudi","year":"2018;","journal-title":"Circulation"},{"key":"key20260223043755_B18","unstructured":"Food and Drug Administration. (2010). Demadex product label. [online] Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/020136s023lbl.pdf."},{"key":"key20260223043755_B19","unstructured":"Food and Drug Administration. (2008). Aldactone\u00ae spironolactone tablets, USP. [online] Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/012151s062lbl.pdf."},{"issue":"(1):","key":"key20260223043755_B20","doi-asserted-by":"crossref","first-page":"19\u2013","DOI":"10.53411\/jpadr.2020.1.1.5","article-title":"Toxic epidermal necrolysis associated with combination therapy of spironolactone and torsemide.","volume":"1","author":"Philip","year":"2020;","journal-title":"JPADR"},{"issue":"(1):","key":"key20260223043755_B21","first-page":"31\u2013","article-title":"Spironolactone + torsemide induced Stevens-Johnson syndrome.","volume":"1","author":"Patel","year":"2021;","journal-title":"J Health Sci Prof Educ"},{"key":"key20260223043755_B22","doi-asserted-by":"crossref","first-page":"S53.","DOI":"10.1016\/j.ihj.2023.11.111","article-title":"Rationale and Study Design of Real-World Effectiveness and Safety of Torsemide and Spironolactone Fixed Dose Combination in Indian Heart Failure Patients (RESTORE-HF Study): A Prospective, Longitudinal, Multicentre, Observational Study.","volume":"75:","author":"Ponde","year":"2023;","journal-title":"Indian Heart J"},{"issue":"(9 Suppl 1):","key":"key20260223043755_B23","first-page":"P40\u2013","article-title":"Fixed-dose combination of torsemide and mineralocorticoid receptor antagonists.","volume":"72","author":"Banerjee","year":"2024;","journal-title":"Indian Heart J"},{"issue":"(21):","key":"key20260223043755_B24","doi-asserted-by":"crossref","first-page":"2281\u2013","DOI":"10.1016\/j.jacc.2014.08.036","article-title":"Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction.","volume":"64","author":"Mentz","year":"2014;","journal-title":"J Am Coll Cardiol"},{"issue":"(37):","key":"key20260223043755_B25","doi-asserted-by":"crossref","first-page":"3686\u2013","DOI":"10.1093\/eurheartj\/ehad522","article-title":"Mineralocorticoid receptor antagonists with sodium\u2013glucose co-transporter-2 inhibitors in heart failure: a meta-analysis.","volume":"44","author":"Banerjee","year":"2023;","journal-title":"Eur Heart J"},{"issue":"(2):","key":"key20260223043755_B26","doi-asserted-by":"crossref","first-page":"117\u2013","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease.","volume":"388","author":"The EMPA-KIDNEY Collaborative Group.","year":"2023;","journal-title":"N Engl J Med"},{"issue":"(15):","key":"key20260223043755_B27","doi-asserted-by":"crossref","first-page":"1436\u2013","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease.","volume":"383","author":"Heerspink","year":"2020;","journal-title":"N Engl J Med"},{"issue":"(8):","key":"key20260223043755_B28","doi-asserted-by":"crossref","first-page":"642\u2013","DOI":"10.1159\/000516213","article-title":"Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage.","volume":"52","author":"Kolkhof","year":"2021;","journal-title":"Am J Nephrol"},{"issue":"(10424):","key":"key20260223043755_B29","doi-asserted-by":"crossref","first-page":"379\u2013","DOI":"10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.","volume":"403","author":"Tuttle","year":"2024;","journal-title":"Lancet"},{"issue":"(10354):","key":"key20260223043755_B30","doi-asserted-by":"crossref","first-page":"757\u2013","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials.","volume":"400","author":"Vaduganathan","year":"2022;","journal-title":"Lancet"},{"issue":"(37):","key":"key20260223043755_B31","doi-asserted-by":"crossref","first-page":"3697\u2013","DOI":"10.1093\/eurheartj\/ehad540","article-title":"Sodium\u2013glucose co-transporter 2 inhibitors and mineralocorticoid receptor antagonists synergism in heart failure: it takes two to tango.","volume":"44","author":"Bauersachs","year":"2023;","journal-title":"Eur Heart J"},{"key":"key20260223043755_B32","doi-asserted-by":"crossref","first-page":"1010693.","DOI":"10.3389\/fcvm.2022.1010693","article-title":"Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: a brief summary.","volume":"9:","author":"Mascolo","year":"2022;","journal-title":"Front Cardiovasc Med"},{"issue":"(4):","key":"key20260223043755_B33","doi-asserted-by":"crossref","first-page":"295\u2013","DOI":"10.1080\/14740338.2019.1602116","article-title":"An update on the safety of SGLT2 inhibitors.","volume":"18","author":"Scheen","year":"2019;","journal-title":"Expert Opin Drug Saf"}],"container-title":["Journal of The Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T04:38:10Z","timestamp":1771821490000},"score":1,"resource":{"primary":{"URL":"https:\/\/japi.org\/article\/japi-74-1-s1-43"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.59556\/japi.74.1301"],"URL":"https:\/\/doi.org\/10.59556\/japi.74.1301","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}